CZI's audacious goal wasn't literal, but a forcing function. When scientists called it impossible, CZI asked "Why?" This revealed the core bottleneck wasn't a lack of therapies, but a lack of shared tools and data. This insight redirected their entire strategy from funding individual grants to building foundational infrastructure for the entire scientific community.
CZI identified a market failure in scientific funding. Government grants favor short-term, small-scale investigations. CZI fills this gap by building long-term, expensive, foundational tools (like imaging and virtual cell models) that accelerate the entire field, rather than just funding the "next best grant."
Cell by Gene began as a tool to solve an internal data annotation bottleneck. By open-sourcing it, CZI unintentionally created a standard data format. The broader scientific community adopted the tool for its utility, organically creating a massive, shared cell atlas built by many contributors, not just CZI.
Traditional grant funding disincentivizes high-risk research because lab work is slow and expensive. Virtual cell models act as a "computational fruit fly," allowing scientists to test radical hypotheses in silico first. This lowers the barrier for exploring unconventional ideas by de-risking the time and resource investment before committing to the wet lab.
Priscilla Chan argues that conditions like hypertension are treated by trial and error because we lump diverse individual biologies together. The goal is to move beyond demographics to a precise, individual-level understanding. By connecting genetic variants to protein expression, every disease treatment becomes effectively personalized, as if it were a "rare" disease.
Most organizations specialize in either frontier AI or frontier biology. CZI's Biohub integrates both to create a tight feedback loop. The AI models identify knowledge gaps, which in turn directs the biology team on what specific data sets to generate next. This flywheel of building bespoke data for model training accelerates discovery much faster than using pre-existing public data.
CZI appointed an AI researcher to head its entire science program. This strategic move signals a belief that the biggest leaps in biology will now be driven by AI expertise, rather than traditional biology expertise supplemented by AI. The leader is now an "AI person who understands biology," not the other way around.
CZI strategically avoids both short-term "bite-sized science" funded by grants and century-long moonshots. Instead, they focus on 10-15 year "grand scientific challenges." This time horizon is long enough to be ambitious but concrete enough to energize teams and demonstrate credible progress, mirroring the lifecycle of a venture-backed company.